Hey, thanks, Stuart.
the the of business. with Let me start commercial side
our the franchise growth. remains foundation DMD Our for
is efforts. there ongoing multiple potential Translarna, growth for For
We early received expect Geographic to increased Brazil, expansion will ANVISA in into for forward. awareness and existing increased moving including growth penetration territories, contribute also disease diagnose territories, which new recently approval.
For prednisone. expect positive with patients Emflaza, we continued those switching momentum new from and
two label are and with DMD treat to patients. and these patients years expansion, we to With able continue increase treatment all now recent the older Emflaza in younger
care prednisone. Journal loss PTC physicians is treatment treatment ensure In possible. to access engaged with a delay with Comparative the associated data deflazacort of in actively payers than further in receive Effectiveness. treatment differentiation with published more with to that with two-year that and was new study, as Our relative recently supported is patients team as of ambulation, Emflaza clinical quickly the to
further treated The the with like positive benefits delayed among in onset deflazacort the from deflazacort and were complications patients was deflazacort switching demonstrated prednisone. also risk-benefit of significantly scoliosis functional prednisone the addition, of data versus In observed patients. the
through launch support Tegsedi and to continues PTC continues with infrastructure upcoming supported PTC well, launch. America The newly genetically to to confirmed leverage ongoing Latin hundreds programs. of our patients strong trend diagnosed
and to nature We is in new the finding are disease, and future. patients process treating due the of the accelerate to likely hereditary the
the was hATTR treatment X for the adult fit patients. polyneuropathic by well-differentiated these X,XXX silencer We hATTR first patients Tegsedi estimated believe in Tegsedi approved Latin stage There Brazil. and in in ANVISA. vast the majority with reminder, them a that X of best for is are an patients America, As
and at-home and the be are at where subcutaneous is requirements challenging, by solution allowing kinds service patients. and our infusion loyalty access professionals. a brand strong early enter able which access patient to support, near build injection travel obtain can relationships. region other a a are our formed best patients is to capacity, healthcare self-administration lasting program, in Through In us clinicals and of for often patients or Tegsedi and
BioE is referenced that touch platform earlier. still me Let upon the now
XXX As and portfolio are mentioned, clinic, programs, are and very we in the advancing future and XX-lipoxygenase. both platforms and current these the targets about within the excited they To and they PTCXXX reiterate, our both stand-alone therapies. with fit
Sumitomo treatment being and different targets Japanese and An a developed ALS of Pharma. a partnered set additional the been neurological Dainippon it with potentially other disease. has compound, of company it's currently And enzymes, for PTCXXX
in has rights the to planning is for Sumitomo study, the North proof-of-concept Japan, positive of Sumitomo PTC forward Latin of Europe. in while of completion rights development including America ALS. commercialization remains PTCXXX recent the America world, and and the Following move with rest commercialization
back in initiating compounds, potential is trial next registrational first our indication epilepsy, be we'll lead quarter. Moving and refractory mitochondrial a PTCXXX, the to
was been to studies. of note, treat rather XXX indication it over series has patients for mitochondrial specific used and PTCXXX with use is unique compassion that Of in already XXX disease studied enrolls. and care expanded of Latin throughout and patients from within XX disease with days in U.S., XXXX inherited XX were were an the program mitochondrial access Europe to America XXXX a end-of-life
which XX also these is alive XX patient and considering criteria, or meaningful the the specific of This expectations less. treatments a was frequency. patients days beginning remarkable survival in experienced There a treatment reduction on today, seizure of at remain of only of XX has
disease randomized baseline upcoming for either have to six epilepsy. will ensure be months. All The month XX frequency or to then and seizure who globally inherited and we mitochondrial be approximately a XXX receive trial, will one PTCXXX associated enroll followed patients for patients placebo refractory
for endpoint the is trial seizure. in reduction The
and to epilepsy U.S. that combined. the addressable there X,XXX expect patients We Europe are X,XXX in mitochondrial
which the registrational plan quarter XXX in to following third should ataxia We approach. quarter, also of Friedreich therapy initiate year, the our in trial this gene another complement with
in XX an to placebo. at trial from when the endpoint show sufficient was neurological In patients history. six with months, treatment measured The was separation in that XXX trial natural an disease private is Phase in to related associated U.S. improvement severity now not long-term and with earlier understands X function FA which in
the have XXX XXX been safety the understandings we incorporating trial, proof-of-concept XXX in been From FA initial dosed the hundreds enroll generally perspective, of the from a fields approximately patients upcoming of trial clinic, emerged the has patients. that tolerated and in since has well in
the for in with younger scheme We will run on focusing randomization trial a a cohorts one-to-one placebo. be and one year
reminder, patients there globally. are that we expect a addressable As XX,XXX FA
as Parkinson's patient third rationale, the quarter. volunteer in first PTCXXX, into Based the Phase are suitable believe a targeting GBA trial we we populations, defined strong healthy will enter larger ideally on the is preclinical Finally for which very indication. X
wanted to I the perspective Now, on Aniridia trial. Translarna, provide some
was Aniridia leads was weeks additional of endpoint defects open-label a For week-XX blindness. caused which baseline gene, is were as with is the randomized nine and weeks placebo-controlled reading for that PAXX the patients often in a in to by genetic extension. patients the older This primary typically accurate trial background, randomized change disorder years by and maximum only speeds XX from six nonsense ocular charts mutation study followed an measured with eight the age. the XX in patients MNREAD than to associated
trend statistical favor did ataluren. of trial the While not observed of a significance, meet in
has data posted slide in reference, our in this conjunction call. the For with deck, been included
forward weeks step, discuss and we intend following the the next program. for with the experts path to a As decide the results on
patients Importantly, use that of to the stage studies ataluren. Aniridia commercial similar and ongoing in previous of the profile was
Moving on DMD. to
results boys XX is year. treatment XX-weeks in This taken XX-week nonsense of with expect the Needle quarter open-label at a study and DMD ataluren baseline biopsies age following the second from We dystrophin trial two seven. to in this ataluren. mutation U.S. single were
as a with for is approval studies. for data from measured as be the we the change With and significant accelerated other results in clinical positive intend The percent dystrophin primary statistically endpoint baseline U.S., submit current conjunction in to from we expect, ECL. the atalauren would by which
program. Moving our deficiency ADC now to
Europe using with identification, all observed have blood patients multipronged increased Latin mimic test been We and continue we approach. palsy after including last testing launching the sample No blood in patient cost for which identification deployed regions globally cerebral America. across was a to make good to that symptoms progress patient epilepsy, and year, in has particularly
platforms. poised As with clinical, across commercial see is regulatory upcoming we continued see, PTCT catalysts growth our you and can all for
the hand Hill. CFO, now will Emily I to our call over
So progress. she can Emily? review the financial
